Waun Ki Hong (1942 – January 2, 2019) was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as Chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993-2005 and as Head of the Division of Cancer Medicine from 2001–2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.
A national and international leader in medical oncology, he trained clinical oncologists throughout the world and participated in creating national cancer policy through the National Cancer Advisory Board (NCAB), the US FDA Oncologic Drug Advisory Committee, the NCI Board of Scientific Advisors, the American Society of Clinical Oncology Board of Directors, and as past president of the American Association for Cancer Research. He was an elected member of the Institute of Medicine (IOM) of the National Academies and an elected Inaugural Fellow of the American Association for Cancer Research (AACR) Academy.
He died at his home in California on January 2, 2019 at the age of 76.
Hong’s specialty was medical oncology, with expertise in the areas of molecular therapeutics, cancer prevention, clinical investigation, and personalized targeted therapy.
His research has affected the following areas:
Hong and his colleagues demonstrated the efficacy of combined chemotherapy and radiotherapy for laryngeal cancer without sacrificing the human larynx. He served as co-study chair for the Veterans Administration Cooperative laryngeal preservation trial, which affected the quality of life for advanced laryngeal cancer patients who previously had no other options except total removal of the voice box. This trial also served as a model for organ preservation in many other cancers such as bladder, breast, and anus.
Hong demonstrated that high-dose retinoids can reverse oral carcinogenesis—a proof of principle that has led to additional ongoing studies in the area of cancer chemoprevention.
Hong initiated a translational research program at MD Anderson Cancer Center using molecularly-targeted approaches for the treatment of lung cancer. He led the BATTLE (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial, which was the first successful prospective randomized trial based on the analysis of molecular findings from real-time biopsies to assign individualized targeted treatment. This trial laid out the groundwork for worldwide development of personalized targeted treatments through the use of tumor profiling.
Hong has played a role in shaping public policy in the United States through his service as chair of the Prevention, Clinical and Therapeutic Subcommittee for the National Cancer Institute (NCI) External Board of Scientific Advisors (BSA); the NCI Translational Research Working Group (TRWG); the U.S. FDA Oncologic Drug Advisory Committee (ODAC); and as chair of the Subcommittee of Clinical Investigations for the National Cancer Advisory Board (NCAB).
His contributions to cancer research have been recognized through national and international awards, including the Raymond Bourgine Award and the Claude Jacquillat Award from the International Congress on Anti-Cancer Treatment (ICACT) in France and the Ho-Am Prize from the Samsung Foundation in Korea. From the AACR, he received the Joseph A. Burchenal and Rosenthal Foundation Awards and the AACR/Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research. From the American Society of Clinical Oncology (ASCO) he received the David Karnofsky Award and the American Cancer Society Award. He also was selected to serve as a member of the ASCO Board of Directors. In 2012, he received the American Cancer Society Medal of Honor for Outstanding Clinical Research.
Hong obtained his medical degree from the Yonsei University School of Medicine, Korea, and completed his medical residency at the Boston Veterans Affairs (VA) Medical Center, followed by a fellowship at Memorial Sloan-Kettering Cancer Center. He served as Chief of Medical Oncology at the Boston VA Medical Center and was a faculty member at both the Boston University School of Medicine and the Tufts University School of Medicine before joining MD Anderson Cancer Center in 1984. He is a Diplomate of the American Board of Internal Medicine (ABIM) in Medical Oncology, and a past member of the Subspecialty Board on Medical Oncology.
Hong has authored more than 685 articles in prestigious scientific journals and edited 11 books. He was a founding editor of Head and Neck Cancer: A Multidisciplinary Approach and Editor-in-Chief of Holland-Frei Cancer Medicine, 8th Edition. He has served on the editorial boards of 17 scientific journals.
Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. This growth can spread beyond the lung by the process of metastasis into nearby tissue or other parts of the body. Most cancers that start in the lung, known as primary lung cancers, are carcinomas. The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). The most common symptoms are coughing, weight loss, shortness of breath, and chest pains.
Lawrence Einhorn is a Distinguished Professor of Medicine at Indiana University School of Medicine and an oncologist. A pioneer in cancer treatment research, Einhorn developed cisplatin-based chemotherapy regimens that increased cure rates while minimizing toxic side effects.
Emil "Tom" Frei III was an American physician and oncologist. He was the former director and former physician-in-chief of the Dana-Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.
Yale Cancer Center (YCC) was founded in 1974 as a result of an act of Congress in 1971, which declared the nation's "war on cancer." It is one of a select network of 49 Comprehensive Cancer Centers throughout the country, designated by the National Cancer Institute (NCI), and the only one in southern New England. Directed by Charles S. Fuchs, MD, MPH, the Cancer Center brings together the resources of the Yale School of Medicine (YSM), Yale New Haven Hospital (YNHH), the Yale School of Public Health (YSPH), and Yale University.
Clinical Lung Cancer is a peer-reviewed medical journal that has been published by Elsevier since 2011. It was established by the CIG Media Group in 1999.
Geriatric oncology is a branch of medicine that is concerned with the diagnosis and treatment of cancer in the elderly, usually defined as aged 65 and older. This fairly young but increasingly important subspecialty incorporates the special needs of the elderly into the treatment of cancer.
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass" and the word λόγος (logos), meaning "study".
Graham Andrew Colditz MD, DrPH is a chronic disease epidemiologist and inaugural Niess-Gain Professor at Washington University School of Medicine, where he is Associate Director for Prevention and Control at the Alvin J. Siteman Cancer Center. He directs the Master of Population Health Science at Washington University School of Medicine. During medical training he was excited by the potential for prevention of chronic diseases. With encouragement from mentors he pursued training in the USA as it was routine for academics in Australia to obtain overseas training at that time. He is internationally recognized for leadership in cancer prevention, and is often interviewed by media for input on this topic. With members of Cancer Prevention and Control at Siteman, he blogs on issues relating to cancer prevention and screening. According to Google Scholar statistics, Colditz is the author with the second highest h-index in the world after Sigmund Freud.
John Mendelsohn was a president of the University of Texas MD Anderson Cancer Center in Houston. He was an internationally recognized leader in cancer research.
Patrick Schöffski is a medical doctor specializing in internal medicine, hematology and medical oncology. He originates from Hannover, Germany, where he also received a master's degree in public health at Hannover Medical School.
Edith A. Perez, M.D., is a Professor of Medicine at Mayo Clinic College of Medicine, Florida. She is a specialist in cancer research, and has authored more than 700 articles in books, journals and abstracts. Perez's work aims to improve the understanding of biological pathways that drive breast cancer, and to improve access to personalized therapies. In 2016, Perez was named as one of '10 LGBT Leaders Reinventing Science and Technology' by Mental Floss and as an 'Outstanding LGBT leader' by the San Francisco Business Times.
Frances Alice Shepherd, is a Canadian oncologist recognized for her research on lung cancer and her contributions to the design, development, and conduct of clinical trials. She is currently a senior staff physician at Princess Margaret Cancer Centre, where she has held the Scott Taylor Chair in Lung Cancer Research since 2001, and she is a full professor in the Department of Medicine at the University of Toronto.
Fadlo R. Khuri is the 16th and current president of the American University of Beirut. He assumed office in September 2015 and was officially inaugurated on January 25, 2016. Khuri is also a professor of the Department of Hematology and Medical Oncology at Emory University School of Medicine and editor-in-chief of the medical journal Cancer.
Michael A. Caliguiri is the president of City of Hope National Medical Center and the physician-in-chief. He was elected president of the American Association for Cancer Research for 2016–2017.
Nancy E. Davidson is the Executive Director and President of Seattle Cancer Care Alliance, Senior Vice President, Director of Clinical Oncology at Fred Hutchinson Cancer Research Center and Head, Division of Medical Oncology, University of Washington School of Medicine. She focuses her research on breast cancer treatments and the genes that are mutated in various forms of breast cancer. She was president of American Association for Cancer Research from 2015–2016 and president of American Society of Clinical Oncology from 2007-2008.
Scott M. Lippman is the director of Moores Cancer Center at the University of California, San Diego and Professor of Medicine at UC San Diego School of Medicine.
Gordon B. Mills is the Wayne and Julie Drinkward Endowed Chair in Precision Oncology, Director of Precision Oncology, Director of SMMART Trials and Professor in Cell, Development and Cancer Biology in the Knight Cancer Institute at Oregon Health Sciences University.
Joseph Rocco Bertino is a researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey. His research is focused on the treatment of lymphoma.
Judy Ellen Garber is the director of the Center for Cancer Genetics and Prevention at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School. Garber previously served as president of the American Association for Cancer Research.